Integra LifeSciences Appoints Sravan Emany as Vice President, Treasurer and Investor Relations
PLAINSBORO, N.J., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Sravan Emany as vice president, treasurer and investor relations. Mr. Emany will be a member of the Integra executive leadership team.
"Sravan has a proven track record of maximizing shareholder value through his extensive involvement in numerous mergers, acquisitions, and corporate financing transactions in the healthcare industry," said Peter Arduini, president and chief executive officer, Integra LifeSciences. "His healthcare experience, financial acumen and market perspective will be invaluable to Integra as we continue to implement our growth strategies, manage our capital structure efficiently, and meet the company's liquidity needs."
Most recently, Mr. Emany was a managing director in the Mergers & Acquisitions group at Bank of America Merrill Lynch. While at Bank of America Merrill Lynch, he led numerous mergers and acquisitions in the healthcare sector, including the recent Integra acquisitions of Codman Neurosurgery and Derma Sciences. Prior to this role, he assumed positions of increasing responsibility in mergers and acquisitions and investment banking at other firms, including Goldman Sachs and Morgan Stanley.
Mr. Emany holds a B.A. in international relations and an M.A. in international relations and international economics from The Johns Hopkins University.
About Integra
Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Investors
Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com
Media
Laurene Isip
609-750-7984
laurene.isip@integralife.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ad36d0eb-459e-4c1e-adca-e35992a090e6